Debra L Foley1, Katherine I Morley. 1. Applied Genetics and Biostatistics, Orygen Youth Health Research Centre, the University of Melbourne, Parkville, Victoria, Australia. dfoley@unimelb.edu.au
Abstract
CONTEXT: The increased mortality associated with schizophrenia is largely due to cardiovascular disease. Treatment with antipsychotics is associated with weight gain and changes in other cardiovascular risk factors. Early identification of modifiable cardiovascular risk factors is a clinical imperative but prospective longitudinal studies of the early cardiometabolic adverse effects of antipsychotic drug treatment other than weight gain have not been previously reviewed. OBJECTIVES: To assess the methods and reporting of cardiometabolic outcome studies of the first treated episode of psychosis, review key findings, and suggest directions for future research. DATA SOURCES: PsycINFO, MEDLINE, and Scopus from January 1990 to June 2010. STUDY SELECTION: Subjects were experiencing their first treated episode of psychosis. Subjects were antipsychotic naive or had been exposed to antipsychotics for a short known period at the beginning of the study. Cardiometabolic indices were assessed. Studies used a longitudinal design. DATA EXTRACTION: Sixty-four articles were identified describing 53 independent studies; 25 studies met inclusion criteria and were retained for detailed review. DATA SYNTHESIS: Consolidated Standards of Reporting Trials and Strengthening the Reporting of Observational Studies in Epidemiology checklists were used to assess the methods and reporting of studies. A qualitative review of findings was conducted. CONCLUSIONS: Two key hypotheses were identified based on this review: (1) in general, there is no difference in cardiovascular risk assessed by weight or metabolic indices between individuals with an untreated first episode of psychosis and healthy controls and (2) cardiovascular risk increases after first exposure to any antipsychotic drug. A rank order of drugs can be derived but there is no evidence of significant class differences. Recommended directions for future research include assessing the effect on cardiometabolic outcomes of medication adherence and dosage effects, determining the therapeutic window for antipsychotic use in adults and youth, and testing for moderation of outcomes by demographic factors, including sex and age, and clinical and genetic factors.
CONTEXT: The increased mortality associated with schizophrenia is largely due to cardiovascular disease. Treatment with antipsychotics is associated with weight gain and changes in other cardiovascular risk factors. Early identification of modifiable cardiovascular risk factors is a clinical imperative but prospective longitudinal studies of the early cardiometabolic adverse effects of antipsychotic drug treatment other than weight gain have not been previously reviewed. OBJECTIVES: To assess the methods and reporting of cardiometabolic outcome studies of the first treated episode of psychosis, review key findings, and suggest directions for future research. DATA SOURCES: PsycINFO, MEDLINE, and Scopus from January 1990 to June 2010. STUDY SELECTION: Subjects were experiencing their first treated episode of psychosis. Subjects were antipsychotic naive or had been exposed to antipsychotics for a short known period at the beginning of the study. Cardiometabolic indices were assessed. Studies used a longitudinal design. DATA EXTRACTION: Sixty-four articles were identified describing 53 independent studies; 25 studies met inclusion criteria and were retained for detailed review. DATA SYNTHESIS: Consolidated Standards of Reporting Trials and Strengthening the Reporting of Observational Studies in Epidemiology checklists were used to assess the methods and reporting of studies. A qualitative review of findings was conducted. CONCLUSIONS: Two key hypotheses were identified based on this review: (1) in general, there is no difference in cardiovascular risk assessed by weight or metabolic indices between individuals with an untreated first episode of psychosis and healthy controls and (2) cardiovascular risk increases after first exposure to any antipsychotic drug. A rank order of drugs can be derived but there is no evidence of significant class differences. Recommended directions for future research include assessing the effect on cardiometabolic outcomes of medication adherence and dosage effects, determining the therapeutic window for antipsychotic use in adults and youth, and testing for moderation of outcomes by demographic factors, including sex and age, and clinical and genetic factors.
Authors: Marc De Hert; Johan Detraux; Ruud van Winkel; Weiping Yu; Christoph U Correll Journal: Nat Rev Endocrinol Date: 2011-10-18 Impact factor: 43.330
Authors: Delbert G Robinson; Nina R Schooler; Majnu John; Christoph U Correll; Patricia Marcy; Jean Addington; Mary F Brunette; Sue E Estroff; Kim T Mueser; David Penn; James Robinson; Robert A Rosenheck; Joanne Severe; Amy Goldstein; Susan Azrin; Robert Heinssen; John M Kane Journal: Am J Psychiatry Date: 2014-12-04 Impact factor: 18.112
Authors: M Alvarez-Jimenez; B O'Donoghue; A Thompson; J F Gleeson; S Bendall; C Gonzalez-Blanch; E Killackey; L Wunderink; P D McGorry Journal: CNS Drugs Date: 2016-05 Impact factor: 5.749
Authors: W Wolfgang Fleischhacker; Celso Arango; Paul Arteel; Thomas R E Barnes; William Carpenter; Ken Duckworth; Silvana Galderisi; Lisa Halpern; Martin Knapp; Stephen R Marder; Mary Moller; Norman Sartorius; Peter Woodruff Journal: Schizophr Bull Date: 2014-04 Impact factor: 9.306
Authors: Vinod H Srihari; Vivek H Phutane; Banu Ozkan; Lydia Chwastiak; Joseph C Ratliff; Scott W Woods; Cenk Tek Journal: Schizophr Res Date: 2013-02-17 Impact factor: 4.939
Authors: María José Morlán-Coarasa; María Teresa Arias-Loste; Víctor Ortiz-García de la Foz; Obdulia Martínez-García; Carmen Alonso-Martín; Javier Crespo; Manuel Romero-Gómez; Emilio Fábrega; Benedicto Crespo-Facorro Journal: Psychopharmacology (Berl) Date: 2016-09-12 Impact factor: 4.530